Kontafarma China Holdings Limited (HKG:1312)

Market Cap	173.25M +6.9%
Revenue (ttm)	891.73M +6.5%
Net Income	-362.77M
EPS	-0.07
Shares Out	5.59B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	650,100
Open	n/a
Previous Close	0.0320
Day's Range	n/a
52-Week Range	0.0200 - 0.0480
Beta	-0.03
RSI	57.03
Earnings Date	Mar 27, 2026

About Kontafarma China Holdings

Kontafarma China Holdings Limited, an investment holding company, manufactures and sells chemical drugs, active pharmaceutical ingredients (API), and API intermediate in Mainland China, Singapore, Taiwan, and internationally. It operates through Pharmaceutical Business and Fitness Business segments. The company offers prescription drugs, including chemical drugs and prescribed traditional Chinese medicines; operates fitness and yoga centers, as well as franchise business; and provides management and consultation services for fitness and health ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2011
• Employees: 655
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1312

Financial Performance

In 2024, Kontafarma China Holdings's revenue was 897.52 million, an increase of 10.93% compared to the previous year's 809.11 million. Losses were -75.54 million, 161.9% more than in 2023.